PPD, Inc. (PPD)
|Net Income (ttm)||120.15M|
|Trading Day||April 19|
|Day's Range||46.15 - 46.49|
|52-Week Range||21.46 - 46.49|
PPD Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of PPD, Inc. Is Fair to Shar...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of PPD, Inc. (NASDAQ: PPD) to Thermo Fisher Scientific Inc. for $47.50 per share is fair...
PPD, Inc. (PPD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t...
NEW YORK, April 15, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of PPD, Inc. ("PPD" or the "Company") (NA...
Medable Secures Another $78 Million Funding to Fuel Digital Innovation for Patient-Centered Drug Development
PALO ALTO, Calif.--(BUSINESS WIRE)-- #biotech--Medable announced $78 million in new funding to fuel advances in the delivery of decentralized clinical trials and patient-centered research.
WALTHAM, Mass. and WILMINGTON, N.C.
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD Announces First Quarter 2021 Earnings Conference Call
Clinical trial leaders PPD and Charles River Labs test resistance and new buy points. The post Clinical Trial Leaders PPD And CRL Stock Test New Buy Points appeared first on Investor's Business Daily.
PPD and Clinical Ink Collaborate on Innovative Process for Lupus Assessment and Near Real-Time Access to Endpoint Data
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD and Clinical Ink have developed a systemic lupus erythematosus (SLE) assessment review process to simplify clinical trials for the chronic disease
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD has been recognized for industry leadership in digital and decentralized clinical trial solutions by Information Services Group (ISG)
PPD, Inc. (PPD) delivered earnings and revenue surprises of 11.43% and 6.39%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD Reports Fourth Quarter and Full Year 2020 Results
PPD, Inc. (PPD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
The year has seen more than 370 companies go public, so finding the 10 best IPOs to invest in won't be easy. Here are the top contenders.
PPD, Inc. (PPD) CEO David Simmons on Q3 2020 Results - Earnings Call Transcript
Investor sentiment remains strong for PPD, as shareholders have enjoyed almost 250% upside since the selloff in March. The stock has bounced away from support 7 times since then, in a narrow ascending c...
HitGen will acquire Vernalis Limited, a Cambridge, UK CRO, from Ligand Pharmaceuticals for $25 million.
PPD saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD Announces Pricing of Secondary Offering of Shares of Common Stock
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD Announces Secondary Offering of Shares of Common Stock.
LOS ANGELES, Aug. 20, 2020 /PRNewswire/ -- Science 37, the industry leader in decentralized clinical trials, today announced it closed an oversubscribed $40 million funding round.
PPD beats the Street by $84.5 million on revenues, but misses EPS by $0.15.
PPD, Inc. (PPD) CEO David Simmons on Q2 2020 Results - Earnings Call Transcript
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq:PPD), a leading global contract research organization, today announced it has signed a new three-year agreement with Pfizer Inc. to provide drug deve...
PPD's (PPD) CEO David Simmons on Q1 2020 Results - Earnings Call Transcript
PPD (NASDAQ: PPD) shares are trading higher on Friday, after Morgan Stanley maintained an Overweight rating and raised its price target from $26 to $30.
PPD - Fully Valued Drug Development Company
PPD Inc. (NASDAQ: PPD) made an exciting entrance to the market Thursday.
PPD Inc. shares soared 14% in their trading debut Thursday, after the drug research company's initial public offering priced at the high end of its $24 to $27 price range.
PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science... [Read more...]
Drug Manufacturers-Specialty & Generic
|IPO Date |
Feb 6, 2020
|Stock Exchange |
|Ticker Symbol |
In 2020, PPD, Inc.'s revenue was $4.68 billion, an increase of 16.14% compared to the previous year's $4.03 billion. Earnings were $153.69 million, an increase of 221.39%.
According to 16 analysts, the average rating for PPD, Inc. stock is "Strong Buy." The 12-month stock price forecast is 43.75, which is a decrease of -5.43% from the latest price.